Drug Trial Radar · NCT05756322
The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jul 20, 2023
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Lin BioScience, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Lin BioScience Pty Ltd
- First posted
- Mar 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most common and severe malignant leukemia in adults and is responsible for the highest mortality from leukemia. ALL is a neoplasm characterized by the growth of malignant lymphoblasts of the B or T lineage, leading to an inhibition of proliferation of the normal blood cell lineages. The primary objectives of this study are investigating the safety, tolerability, and the MTD of LBS-007. The secondary objectives are to assess the efficacy and to determine the pharmacokinetics (PK) of LBS-007. The exploratory objective is to study and correlate the changes in surrogate biomarkers in response to treatment.
Conditions
- Relapsed or Resistant Acute Leukaemias
Interventions
LBS-007Drug
Open Label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number, severity and duration of adverse events (AEs) and treatment-related AEs according to Common Terminology Criteria for Adverse Events (CTCAE) v5.Time frame: From baseline through 28 days after end of last treatment cycle (up to 12 months)
- Recommended Phase 2 Dose (RP2D) of LBS-007 in the subject population.Time frame: From baseline through 28 days after end of last treatment cycle (up to 12 months)
Locations
17 sites in 4 countries. Site status is shown where the registry gives one.
Moffitt Cancer Center
Tampa, Florida · Recruiting
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois · Not yet recruiting
The University of Kansas Hospital
Fairway, Kansas · Recruiting
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland · Recruiting
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Wollongong Private Hospital
Wollongong, New South Wales, Australia · Completed
Pindara Private Hospital
Benowa, Queensland, Australia · Completed
The Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Active not recruiting
Hollywood Private Hospital
Nedlands, Washington, Australia · Withdrawn
Q Medical Conselling
Perth, Washington, Australia · Withdrawn
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China · Recruiting
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China · Recruiting
Jining No.1 People's Hospital
Jining, Shandong, China · Recruiting
China Medical University Hospital
Taichung, Taiwan · Not yet recruiting
National Cheng Kung University Hospital
Tainan, Taiwan · Not yet recruiting
National Taiwan University Hospital
Taipei, Taiwan · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.